Am J Transplant, Volume 19, Suppl 3 Archives - Page 135 of 214 - ATC Abstracts

2019 American Transplant Congress
Assessment of Culture/Preservation Conditions on Survival and Function of Islets
Y. Shindo, M. F. Levy, M. A. Kanak
Surgery, Virginia Commonwealth University, Richmond, VA
*Purpose: Culture or preservation of human islets prior to transplantation has been adopted by various centers because it may reduce immunogenicity, suppress exocrine contamination and…
2019 American Transplant Congress
B Cell Derived Exosomes Are Associated with Antibody Mediated Rejection in Kidney Transplant Recipients Desensitized for a Positive Cross-Match
D. Cucchiari¹, V. Tubita², M. J. Ramirez-Bajo², J. Rovira², F. E. Borràs³, L. Carreras-Planella³, A. Hertig⁴, F. Oppenheimer¹, F. Diekmann¹, I. Revuelta¹
¹Renal Transplant Unit, Hospital Clínic, Barcelona, Spain, ²Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain, ³REMAR-IVECAT group, IGTP, Badalona, Spain, ⁴Department of Nephrology and Kidney Transplantation, Hôpital Tenon, Paris, France
*Purpose: Kidney transplant recipients undergoing desensitization for a positive cross-match are at very high risk of developing Antibody-Mediated Rejection (AMR). Because of desensitization, peripheral circulating…
2019 American Transplant Congress
Surveillance Biopsy Utilization Reported Higher In Transplant Centers Performing Over 100 Kidney Transplants Per Year.
D. M. Lee¹, R. First¹, S. Rose¹, M. Abecassis²
¹Transplant Genomics Inc, Mansfield, MA, ²Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: To assess the frequency of surveillance biopsies in kidney transplant patients in transplant centers performing greater than 100 transplants per year, and to compare…
2019 American Transplant Congress
Symptom Burden after Living Donor Kidney Transplant Measured with the Functional Assessment of Cancer Therapy – Kidney Symptom Index is Associated with Worse Transplant Outcomes
J. Peipert, J. Caicedo-Ramirez, K. Ensor, J. Friedewald, M. Abecassis, D. Cella, D. Ladner, Z. Butt
Northwestern University, Chicago, IL
*Purpose: As the FDA and other stakeholders in transplantation look for fit-for-purpose (FFP) patient-reported outcome measures, there is a need to better understand symptom burden…
2019 American Transplant Congress
Donor-Derived Cell-Free DNA is Associated Specifically with Antibody Mediated Injury in Patients with Renal Allograft Dysfunction
B. Obrisca¹, C. Blosser², I. De Castro², C. Johnson², B. Sorohan¹, L. Sibulesky², R. Bakthavatsalam², G. Ismail¹, N. Leca²
¹Fundeni Clinical Institute, Bucharest, Romania, ²University of Washington, Seattle, WA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a noninvasive biomarker to differentiate rejection from other types of injury in renal allografts.*Methods: We analyzed…
2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
T. Hiramitsu, T. Tomosugi, K. Futamura, M. Okada, M. Tsujita, T. Ichimori, N. Goto, S. Narumi, Y. Watarai
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…
2019 American Transplant Congress
ilearnKAS: An Animated Video to Educate African Americans about Key Concepts of Kidney Allocation
J. Narvaez, B. Dolph, T. Feeley, L. Kayler
University at Buffalo, Buffalo, NY
*Purpose: ilearnKAS is a iteratively-designed patient-engaged mobile educational animated video developed with guidance from patients, providers, Self-efficacy and Multimedia Learning Theories designed for African American…
2019 American Transplant Congress
Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival
T. Jouve¹, J. Noble¹, X. Fonrose², B. Janbon¹, G. Fiard³, P. Malvezzi¹, L. Rostaing¹
¹Nephrology, Dialysis, Aphereses and Transplantation Department, Grenoble University Hospital, Grenoble, France, ²Pharmacology, Pharmacogenetics and Toxicology Laboratory, Grenoble University Hospital, Grenoble, France, ³Urology and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France
*Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…
2019 American Transplant Congress
Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)
K. Budde¹, S. Bunnapradist², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, B. Suwelack⁴
¹Charité University Medicine Berlin, Berlin, Germany, ²UCLA Medical Center, Los Angeles, CA, ³Veloxis Pharmaceuticals Inc., Cary, NC, ⁴University Hospital of Münster, Münster, Germany
*Purpose: Early achievement of therapeutic tacrolimus concentrations has been associated with reduced rates of acute rejection. A prospective, randomized, controlled study demonstrated safe and efficacious…
2019 American Transplant Congress
Relationship between Comorbilities and Infectious Disease in Kidney Transplant Recipients Receiving Rituximab
A. Molina-Andújar¹, E. Hermida¹, J. Rovira², F. Cofan¹, P. Ventura-Aguiar¹, N. Esforzado¹, V. Torregrosa¹, D. Cucchiari¹, E. de Souza¹, I. Revuelta¹, F. Oppenheimer¹, F. Diekmann¹, G. Piñeiro¹
¹Renal Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain, ²Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain
*Purpose: Rituximab is commonly used in the context of kidney transplantation. Evidence about infectious complications and its relationship with predictive factors is scarce. The aim…